Tolerability of oral nutrition for interstitial lung disease with weight loss tendency
- Conditions
- interstitial lung disease
- Registration Number
- JPRN-jRCTs031220119
- Lead Sponsor
- Abe Mitsuhiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3
1) Patients diagnosed with interstitial lung disease
2) Patients aged 20 years and over at the time of obtaining consent
3) Patients with weight loss of at least 1 kg in the last 12 months
4) Patients who have been fully informed of the study and have obtained documentation of their own free will with full understanding of their participation in the study.
1) Patients with coexisting malignant disease
2) Patients with other diseases such as diabetes causing weight loss
3) Patients already taking oral nutritional supplements at least once a week
4) Patients receiving new medication within the past month for diarrhea as a side effect of antifibrotic drugs
5) Patients allergic to milk, soya and gelatine, which are ingredients of Isocal 100
6) Patients unable to give consent
7) Other patients deemed unsuitable for the safe conduct of the study by the principal investigator or the sub-investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method